Role of type 2 immunity in intestinal inflammation

被引:55
作者
Bamias, Giorgos [1 ]
Cominelli, Fabio [2 ]
机构
[1] Kapodistrian Univ Athens, Acad Dept Gastroenterol, Laikon Hosp, Athens 11527, Greece
[2] Case Western Reserve Univ, Sch Med, Div Gastrointestinal & Liver Dis, Cleveland, OH USA
基金
美国国家卫生研究院;
关键词
helminths; ILC2; inflammatory bowel disease; mucosal immunity; type; 2; responses; INNATE LYMPHOID-CELLS; CD4(+) T-CELLS; ULCERATIVE-COLITIS; MONOCLONAL-ANTIBODY; DENDRITIC CELLS; PHASE IIA; B-CELLS; IL-33; RESPONSES; MICE;
D O I
10.1097/MOG.0000000000000212
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose of reviewType 2 (Th2) immune responses play important roles in intestinal immunity by contributing to the maintenance of mucosal homeostasis, not only conferring protection against helminthic infection but also participating in pro-inflammatory pathways in chronic intestinal inflammatory disorders, including inflammatory bowel disease. The current review focuses on recent developments regarding the role of Th2 responses in intestinal inflammation.Recent findingsTh2 gut mucosal responses are promoted by mediators that are released following injury to the epithelium, and act as alarmin-type danger signals. Interleukin (IL)-33 is prominent among such factors and demonstrates a dichotomous function, exerting either protective or pro-inflammatory effects, depending on its cellular compartmentalization. The pool of type 2 effector cells has been enriched recently to include not only classical CD4+ Th2 lymphocytes but also a subset of innate lymphocytes (ILC2s) that express the transcriptional factor GATA binding protein 3 and secrete IL-4, IL-5, and IL-13. ILC2s play important roles during infection with helminths and bi-directionally interact with Th2 CD4+ lymphocytes, thus establishing a transition from innate to adaptive immunological pathways. Th2 responses are also involved in pro-inflammatory pathways at the intestinal mucosa, and neutralization of the pivotal cytokines IL-4 and IL-13 has been shown to regulate experimental intestinal inflammation. In striking contrast, however, neutralization of human IL-13 had no therapeutic effect in patients with ulcerative colitis.SummaryFurther studies will be required to delineate the specific mechanisms of type 2 mucosal immunity in inflammatory bowel disease and examine the applicability of Th2-targeted therapies for intestinal inflammation.
引用
收藏
页码:471 / 476
页数:6
相关论文
共 40 条
[1]   Host protective roles of type 2 immunity: Parasite killing and tissue repair, flip sides of the same coin [J].
Allen, Judith E. ;
Sutherland, Tara E. .
SEMINARS IN IMMUNOLOGY, 2014, 26 (04) :329-340
[2]   The 3 major types of innate and adaptive cell-mediated effector immunity [J].
Annunziato, Francesco ;
Romagnani, Chiara ;
Romagnani, Sergio .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (03) :626-635
[3]   Immunopathogenesis of inflammatory bowel disease: current concepts [J].
Bamias, Giorgos ;
Cominelli, Fabio .
CURRENT OPINION IN GASTROENTEROLOGY, 2007, 23 (04) :365-369
[4]   New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation [J].
Bamias, Giorgos ;
Corridoni, Daniele ;
Pizarro, Theresa T. ;
Cominelli, Fabio .
CYTOKINE, 2012, 59 (03) :451-459
[5]   Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation [J].
Bessa, Juliana ;
Meyer, Claas Aiko ;
Mudry, Maria Cristina de Vera ;
Schlicht, Sonja ;
Smith, Susan H. ;
Iglesias, Antonio ;
Cote-Sierra, Javier .
JOURNAL OF AUTOIMMUNITY, 2014, 55 :33-41
[6]   Indigenous enteric eosinophils control DCs to initiate a primary Th2 immune response in vivo [J].
Chu, Derek K. ;
Jimenez-Saiz, Rodrigo ;
Verschoor, Christopher P. ;
Walker, Tina D. ;
Goncharova, Susanna ;
Llop-Guevara, Alba ;
Shen, Pamela ;
Gordon, Melissa E. ;
Barra, Nicole G. ;
Bassett, Jennifer D. ;
Kong, Joshua ;
Fattouh, Ramzi ;
McCoy, Kathy D. ;
Bowdish, Dawn M. ;
Erjefalt, Jonas S. ;
Pabst, Oliver ;
Humbles, Alison A. ;
Kolbeck, Roland ;
Waserman, Susan ;
Jordana, Manel .
JOURNAL OF EXPERIMENTAL MEDICINE, 2014, 211 (08) :1657-1672
[7]   Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study [J].
Danese, Silvio ;
Rudzinski, Janusz ;
Brandt, Wolfgang ;
Dupas, Jean-Louis ;
Peyrin-Biroulet, Laurent ;
Bouhnik, Yoram ;
Kleczkowski, Dariusz ;
Uebel, Peter ;
Lukas, Milan ;
Knutsson, Mikael ;
Erlandsson, Fredrik ;
Hansen, Mark Berner ;
Keshav, Satish .
GUT, 2015, 64 (02) :243-249
[8]   Where are we on worms? [J].
Elliott, David E. ;
Weinstock, Joel V. .
CURRENT OPINION IN GASTROENTEROLOGY, 2012, 28 (06) :551-556
[9]  
Elliott DE, 2009, ADV EXP MED BIOL, V666, P157
[10]   Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis [J].
Fuss, IJ ;
Heller, F ;
Boirivant, M ;
Leon, F ;
Yoshida, M ;
Fichtner-Feigl, S ;
Yang, ZQ ;
Exley, M ;
Kitani, A ;
Blumberg, RS ;
Mannon, P ;
Strober, W .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (10) :1490-1497